Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 63 Georgia 57 Florida 56 Colorado 41 Arizona 38
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC9 AbbVie6 Regeneron Pharmaceuticals3 Pfizer3 Karyopharm Therapeutics Inc1
State
California63 Georgia57 Florida56 Colorado41 Arizona38
All 42 states
Target enrolment
to

Trials with a site in New York

37 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1/2
360
Arizona, California, Georgia, New York, Texas
2026-09-30
Recruiting
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Recruiting
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Active, closed
Janssen Research & Development, LLC
Phase 2
11
Iowa, Kentucky, Michigan, New York, Pennsylvania
2024-09-16
Active, closed
Cullinan Therapeutics Inc.
Phase 1
30
Arizona, Florida, Minnesota, New York, North Carolina, Texas
2024-09-03
Recruiting
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Active, closed
Janssen Research & Development, LLC
Phase 2
43
California, Iowa, New York, North Carolina
2024-08-20
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Recruiting
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Recruiting
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Active, closed
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
All4Cure
Observational
200
Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington
2023-03-01
Recruiting
K36 Therapeutics, Inc.
Phase 1
165
California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2023-02-22
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Florida, Georgia, Michigan, Missouri, New York, Texas
2022-12-15
Recruiting
Pfizer
Phase 3
1,060
Florida, Nebraska, Nevada, New Jersey, New York, Texas, Utah
2022-11-10
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Alabama, Maryland, Massachusetts, New Jersey, New York
2022-10-18
Active, closed
Hoffmann-La Roche
Phase 1/2
90
Colorado, Florida, Maryland, Massachusetts, Minnesota, New York, Tennessee, Utah
2022-10-17
Recruiting
Regeneron Pharmaceuticals
Phase 1
317
California, Georgia, Indiana, Massachusetts, Michigan, Minnesota, New York, North Carolina
2022-08-17
Recruiting
Heidelberg Pharma AG
Phase 1/2
78
Georgia, Kentucky, Nebraska, New York, Texas
2022-02-07
Recruiting
Pfizer
Phase 3
893
California, Colorado, Florida, Louisiana, New Jersey, New York
2021-10-04
Active, closed
Janssen Research & Development, LLC
Phase 1
166
Alabama, California, Colorado, Georgia, Indiana, New Jersey, New York, North Carolina
2021-09-22
Active, closed
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell
DrugsDarzalex·Selinexor·Daratumumab·Lenalidomide
US Oncology Research
Phase 2
73
Arizona, Colorado, Maryland, New York, Oregon, Texas, Virginia
2021-09-10
Active, closed
Janssen Research & Development, LLC
Phase 1
140
Alabama, California, Colorado, Georgia, Indiana, Missouri, New Jersey, New York
2021-03-12
Active, closed
Pfizer
Phase 2
187
California, Florida, Georgia, Illinois, Kentucky, Louisiana, New Jersey, New York
2021-02-02
Active, closed
Janssen Research & Development, LLC
Phase 1/2
228
Alabama, Arkansas, Colorado, Georgia, Minnesota, Missouri, New York, North Carolina
2020-12-15
Active, closed
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
100
Arizona, California, Kansas, New York, Oregon, Washington
2020-04-13
Active, closed
GlaxoSmithKline
Phase 3
325
Arizona, Colorado, Michigan, Nebraska, New York, Ohio, Oregon, Texas
2020-04-02
Active, closed
Janssen Research & Development, LLC
Phase 1
290
California, New York, North Carolina, Pennsylvania, Tennessee, Wisconsin
2020-02-21
Active, closed
AbbVie
Phase 1/2
220
California, Louisiana, Minnesota, Missouri, New York, North Carolina, Wisconsin
2019-06-24
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Florida, Georgia, Indiana, Kentucky, Michigan, New Jersey, New York, Ohio
2019-01-23
Active, closed
AbbVie
Phase 2
156
Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, North Carolina
2018-04-02
Active, closed
PRospective Multiple Myeloma Impact Study
NCT02911571Multiple Myeloma
SkylineDx
Not applicable
250
District of Columbia, Georgia, New Jersey, New York, North Carolina, Wisconsin
2018-02-27
Active, closed
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02477878Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
DrugRimiducid
Bellicum Pharmaceuticals
Phase 1
10
Georgia, Kansas, New York, Oregon, Texas
2016-07
Recruiting
Karyopharm Therapeutics Inc
Phase 1/2
300
Arizona, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2015-10
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in New York that also match the filters currently applied.

How many clinical trials are recruiting in New York?

19 of the 37 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New York), 37 studies
PhaseStudiesRecruitingShare
Phase 1/2131035.1%
Phase 19324.3%
Phase 27218.9%
Phase 35313.5%
Not applicable102.7%
Observational102.7%
Phase 2/3112.7%

Most active sponsors

Lead sponsors with the most studies (New York)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC92
AbbVie64
Pfizer32
Regeneron Pharmaceuticals33
All4Cure10
AstraZeneca11
Bellicum Pharmaceuticals10
Bristol-Myers Squibb11
Cullinan Therapeutics Inc.10
Fortvita Biologics (USA)Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.